Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ANIK 
Anika Therapeutics Inc (ANIK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ANIK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $17.33
1 Year Target Price $17.33
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.21% | Avg. Invested days 59 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 133.08M USD | Price to earnings Ratio - | 1Y Target Price 17.33 |
Price to earnings Ratio - | 1Y Target Price 17.33 | ||
Volume (30-day avg) 3 | Beta 0.64 | 52 Weeks Range 7.87 - 26.00 | Updated Date 08/28/2025 |
52 Weeks Range 7.87 - 26.00 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When - | Estimate -0.08 | Actual -0.13 |
Profitability
Profit Margin -52.93% | Operating Margin (TTM) -14.81% |
Management Effectiveness
Return on Assets (TTM) -2.4% | Return on Equity (TTM) -7.23% |
Valuation
Trailing PE - | Forward PE 909.09 | Enterprise Value 104179066 | Price to Sales(TTM) 1.16 |
Enterprise Value 104179066 | Price to Sales(TTM) 1.16 | ||
Enterprise Value to Revenue 0.91 | Enterprise Value to EBITDA -72.65 | Shares Outstanding 14418100 | Shares Floating 10362570 |
Shares Outstanding 14418100 | Shares Floating 10362570 | ||
Percent Insiders 4.88 | Percent Institutions 89.45 |
Upturn AI SWOT
Anika Therapeutics Inc
Company Overview
History and Background
Anika Therapeutics, founded in 1992, specializes in developing and commercializing therapeutic products for tissue protection, healing, and repair. Initially focused on hyaluronic acid (HA)-based technologies, it has expanded its portfolio through acquisitions and internal development.
Core Business Areas
- Joint Pain Management: Anika's primary focus is on therapies for osteoarthritis, including viscosupplements that use hyaluronic acid to lubricate and cushion joints.
- Sports Medicine: Offering products for soft tissue repair, including rotator cuff and meniscus repair, often using HA-based technologies.
- Regenerative Solutions: Developing and marketing regenerative medicine products that promote tissue healing and regeneration.
- Orthopedics: Offering solutions for bone healing and related orthopedic applications.
Leadership and Structure
Anika has a management team led by its CEO, and its organizational structure typically includes departments for R&D, sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Monovisc: A single-injection viscosupplement for osteoarthritis knee pain. Competitors include Sanofi (SNY) and Zimmer Biomet (ZBH). Market share varies regionally but is significant in the single-injection viscosupplement market. While specific figures fluctuate, it's a key revenue driver.
- Orthovisc: A multi-injection viscosupplement for osteoarthritis knee pain. Competitors include Sanofi (SNY) and Zimmer Biomet (ZBH). Similar to Monovisc, market share depends on region and market dynamics, also contributes significantly to revenue.
- Cingal: A single-injection viscosupplement with triamcinolone acetonide, a corticosteroid, for osteoarthritis knee pain. Competitors include Sanofi (SNY) and Zimmer Biomet (ZBH).
Market Dynamics
Industry Overview
The orthopedic and sports medicine market is growing, driven by an aging population, increasing rates of osteoarthritis, and advancements in minimally invasive surgical techniques.
Positioning
Anika is positioned as a leader in hyaluronic acid-based therapies for joint pain and soft tissue repair. Its competitive advantage lies in its established brand, product portfolio, and strong relationships with orthopedic surgeons.
Total Addressable Market (TAM)
The global osteoarthritis treatment market is expected to reach tens of billions of dollars. Anika is positioned to capture a portion of this market through its viscosupplements and regenerative medicine products. It is actively developing new products to increase it's TAM.
Upturn SWOT Analysis
Strengths
- Established brand reputation
- Strong portfolio of HA-based products
- Relationships with orthopedic surgeons
- Focus on innovation in regenerative medicine
Weaknesses
- Reliance on HA technology; limited product diversification
- Competition from larger orthopedic companies
- Pricing pressures in the viscosupplement market
- Dependence on regulatory approvals for new products
Opportunities
- Expansion into new geographic markets
- Development of novel regenerative medicine therapies
- Acquisition of complementary technologies or products
- Partnerships with hospitals and clinics
Threats
- Increased competition from biosimilars
- Changes in reimbursement policies
- Product liability claims
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- SNY
- ZBH
- SLP
Competitive Landscape
Anika competes with larger orthopedic companies that have greater resources and broader product portfolios. Anika specializes in niche markets.
Major Acquisitions
Parcus Medical
- Year: 2019
- Acquisition Price (USD millions): 55
- Strategic Rationale: Expanded Anika's sports medicine portfolio with complementary products and technologies.
Arthrosurface
- Year: 2020
- Acquisition Price (USD millions): 150
- Strategic Rationale: Broadened Anikau2019s product portfolio in joint preservation and restoration.
Growth Trajectory and Initiatives
Historical Growth: Anika's historical growth is a result of market demand for its core products and strategic acquisitions. It depends on its product sales and adoption rate.
Future Projections: Future growth is dependent on the success of new product development, regulatory approvals, and market adoption. Analyst estimates should be consulted for detailed projections.
Recent Initiatives: Recent initiatives include expanding the portfolio of pain management solutions, investing in regenerative medicine research, and exploring new market opportunities.
Summary
Anika Therapeutics is a specialty biotech firm focusing on osteoarthritis treatment, particularly viscosupplementation. Its strong HA portfolio and established brand are significant strengths. However, it faces competition from larger firms and reliance on a core technology poses risks. Future growth will hinge on new product development and market expansion.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Market research reports
- Analyst estimates
- SEC filings
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data is approximate and based on available information, subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anika Therapeutics Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 1993-04-29 | President, CEO & Director Dr. Cheryl Renee Blanchard Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 288 | Website https://www.anika.com |
Full time employees 288 | Website https://www.anika.com | ||
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.